Health and Fitness Health and Fitness
Wed, December 28, 2011
Tue, December 27, 2011
[ Tue, Dec 27th 2011 ] - Market Wire
EGM 8 February 2012

Mylan Receives Approval for First-to-File Generic Keppra XR Extended-Release Tablets


Published on 2011-12-27 04:05:44 - Market Wire
  Print publication without navigation


Mylan Receives Approval for First-to-File Generic Keppra XR? Extended-Release Tablets -- PITTSBURGH, Dec. 27, 2011 /PRNewswire/ --

Mylan Receives Approval for First-to-File Generic Keppra XR? Extended-Release Tablets

[ ]

Company shares first-to-file marketing exclusivity on all strengths

PITTSBURGH, Dec. 27, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: [ MYL ]) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Extended-release (ER) Tablets, 500 mg and 750 mg. This product is the generic version of UCB's Keppra XR® Tablets, which are a treatment for partial onset seizures in patients over 16 years of age with epilepsy. 

Levetiracetam ER Tablets had U.S. sales of approximately $162.8 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 170 ANDAs pending FDA approval representing $98.4 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.8 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit [ www.mylan.com ]. For more information about generic drugs, please visit [ www.ChoosingGenerics.com ].

 

 

SOURCE Mylan Inc.

[ Back to top ]

RELATED LINKS
[ http://www.mylan.com ]